Abstract
Cancer is one of the major challenges in medicine, necessitating continuous advancements in therapeutic approaches. Autophagy, an intracellular pathway essential for cellular homeostasis and stress response, has emerged as a promising target for cancer treatment. In this context, FAM46C, a novel pan-cancer tumour suppressor, has been shown to induce apoptosis in multiple myeloma cells through indirect inhibition of autophagy. Here, we discuss how FAM46C-induced autophagic dampening could offer new opportunities for global cancer therapy. Specifically, we explore two scenarios in which the expression of a functional FAM46C may either sensitize cancer cells to autophagic inhibition or antagonize their sensitivity. We further comment on how this synergism/antagonism could be used to refine strategies for cancer treatment, positioning FAM46C as a pivotal factor in future cancer therapy development.